Diagnosis and Management of Infantile Hemangioma

Elocon®
(mometason
e furoate) 11
Topical
cream
Corticosteroid indicated for
the relief of the inflammatory
and pruritic manifestations
of corticosteroid-responsive
dermatoses in patients 2
years of age or older
--- • Reversible HPA axis suppression with the potential for
glucocorticosteroid insufficiency after withdrawal of treatment,
Cushing's syndrome, and hyperglycemia may occur due to
systemic absorption. Patients applying a topical steroid to a large
surface area or to areas under occlusion should be evaluated
periodically for evidence of HPA axis suppression. Modify use
should HPA axis suppression develop.
• Pediatric patients may be more susceptible to systemic toxicity.
• Allergic Contact Dermatitis: If irritation develops, mometasone
furoate should be discontinued and appropriate therapy instituted.
• Concomitant Skin Infections: If concomitant skin infections are
present or develop, an appropriate antifungal or antibacterial agent
should be used. If a favorable response does not occur promptly,
mometasone furoate use of should be discontinued until the
infection has been adequately controlled.
Zyclara®
(imiquimod) 1
2
Aldara®
(imiquimod) 1
3
2.5% to
3.75%
Topical
cream
5% Topical
cream
Indicated for the treatment
of external genital and
perianal warts
(EGW)/condyloma
acuminata in patients 12
years or older.
--- • Local Skin Reactions: Intense local skin reactions including skin
weeping or erosion can occur after a few applications and may
require an interruption of dosing. Imiquimod has the potential to
exacerbate inflammatory conditions of the skin, including chronic
graft versus host disease.
Severe local inflammatory reactions of the female external genitalia
can lead to severe vulvar swelling. Severe vulvar swelling can lead
to urinary retention. Dosing should be interrupted or discontinued
for severe vulvar swelling.
Administration of imiquimod is not recommended until the skin is
healed from any previous drug or surgical treatment.
• Systemic Reactions Flu-like signs and symptoms may accompany,
or even precede, local skin reactions and may include fatigue,
nausea, fever, myalgias, arthralgias, malaise and chills.
• Ultraviolet Light Exposure Risks: Exposure to sunlight (including
sunlamps) should be avoided or minimized during use of
imiquimod.
• Increased Risk of Adverse Reactions with Concomitant Imiquimod
Use
• Immune Cell Activation in Autoimmune Disease: Imiquimod should
be used with caution in patients with pre-existing autoimmune
conditions because imiquimod activates immune cells
H-9